Business Wire | November 02, 2023
Absolute Software™, the leading provider of self-healing, intelligent security solutions, today announced the launch of Absolute Application Health. This new feature empowers digital enterprises to strengthen cyber resilience and boost end user productivity with the industry’s most resilient application health monitoring capabilities. With this latest innovation to the company’s Secure Endpoint product line, customers can monitor the health of more than 2,000 commonly used Windows and Mac applications – including security controls, business, and productivity tools – to ensure they are installed, running, and properly configured on all devices.
“Organizations deploy millions of endpoint devices to support growing remote workforces around the world, and they invest billions of dollars into security controls needed to protect their networks against advanced threats and costly compliance violations,” said Sarah Pavlak, Industry Principal, Frost & Sullivan. “Despite all these efforts and money spent, organizations continue to experience increasing attacks and complexity challenges that severely disrupt business operations. This is leading to a continual need for innovations that can mitigate software failures and close security gaps.”
Absolute’s 2023 Resilience Index reveals that on average, enterprise endpoint devices have 67 applications deployed, with 10 percent of these having more than 100 applications installed. In analyzing 10 of the most widely deployed security tools, the report also shows seven of those 10 apps were installed and healthy on less than 80 percent of deployed devices, on average. In some cases, apps were only functioning correctly 47 percent of the time.
said John Herrema, Chief Product Officer, Absolute Software.
Today’s digital enterprises are investing billions of dollars in mission-critical security and business tools, and we believe those applications should deliver their intended value. The complexity and fragility of endpoint applications, however, means that all too often they are failing. And if the tool you use to monitor your other applications is subject to those same failures, then you’re really in trouble, because it’s impossible to fix what you can’t reliably see or diagnose. This latest innovation builds on Absolute’s unique Persistence technology to provide the industry’s most resilient visibility and monitoring capabilities. This allows our customers to achieve maximum security, productivity, and return on their software investments.
With Absolute Application Health, IT and security practitioners gain the deep visibility needed to ensure applications are installed, running, up-to-date, and properly configured across their entire device fleet. They also have access to detailed, interactive reports and widgets that enable them to swiftly diagnose why an application is failing and then take remedial action.
Embedded in the firmware of more than 600 million devices, Absolute’s patented Persistence® technology provides a secure, always-on connection between the Absolute Platform and the endpoint. The new Application Health feature leverages this digital tether to ensure health monitoring and reporting remains uninterrupted.
Absolute Application Health is available now to Absolute Secure Endpoint customers subscribed to eligible Absolute Resilience licenses. For more information, including how to access and activate this new feature, visit our latest blog.
About Absolute Software
Absolute Software makes security work. We empower mission-critical performance with advanced cyber resilience. Embedded in more than 600 million devices, our cyber resilience platform delivers endpoint-to-network access security coverage, ensures automated security compliance, and enables operational continuity. Nearly 21,000 global customers trust Absolute to protect enterprise assets, fortify security and business applications, and provide a frictionless, always-on user experience.
PR Newswire | October 17, 2023
Home Care Delivered, Inc. a leader in providing medical supplies including diabetes/CGM, incontinence, wound, urological, and ostomy products, is excited to announce the successful acquisition of Medline Industries, LP's DMEPOS supplier business unit.
This strategic move will significantly enhance HCD's market presence, expand its geographical footprint, and provide access to a broader customer base while reinforcing relationships with patients, healthcare plans and providers, and manufacturers.
"The transaction represents a major milestone for HCD by leveraging over 25 years of distinguished expertise in medical supplies," said Gordy Fox, founder and chief executive officer of HCD. "This acquisition aligns with our commitment to delivering personalized and compassionate customer experiences while leveraging Medline's DMEPOS supplier assets, and continuing to provide our industry expertise and best-in-class customer service."
said Brad Mariam, executive vice president, Medline.
With the transition of Medline's DMEPOS supplier assets to HCD, a company that shares in our commitment to exceptional service and patient care, Medline will continue to focus on its core role as an industry leader in the manufacturing and distribution of quality medical supplies.
[Source: PR Newswire]
"By integrating Medline's DMEPOS supplier assets, we are accelerating our growth strategy, delivering an avenue for expanded cost-efficiencies and member adherence," said Lowell Price, senior vice president of business development and chief growth officer of HCD. "This strategic move aligns with our commitment to delivering superior customer service, additional product offerings and ensuring reliable delivery to our members. HCD is well-positioned to continue to elevate customer experiences and reinforce our market presence."
About Home Care Delivered, Inc.
Home Care Delivered is a leading direct-to-consumer provider of insurance-covered medical supplies of diabetes testing, incontinence, urology, ostomy and wound care supplies delivered directly to the patient's home. Founded in 1996 and headquartered in Glen Allen, Virginia, Home Care Delivered is dedicated to providing best-in-class customer support and quality supplies for patients and caregivers nationwide.
Health Technology, Healthcare Analytics
businesswire | September 27, 2023
Weave a leading all-in-one experience platform for small and medium-sized healthcare businesses, announced a new partnership with Affirm the payment network that empowers consumers and helps merchants drive growth. Now available to thousands of Weave’s customers, this collaboration provides flexible payment options for eligible patients, making it easier for them to access and afford the care they need.
By partnering with Affirm, Weave customers can offer their patients pay-over-time financing with as low as 0% APR. Affirm is directly integrated with Weave payments, so patients can apply to pay with Affirm in a matter of seconds, and spread out their payments over time, easing the burden of upfront costs and providing an additional payment option for dental, optometry, veterinary, or medical practices. This partnership will not only benefit patients but also allow healthcare practices to receive payments quicker than before.
“Collecting payments is one of the most important parts of the patient's journey. A smooth and efficient payment process can help to create a positive patient experience, build trust, and encourage repeat business, which is why we are excited to partner with Affirm,” said Branden Neish, Chief Product & Technology Officer of Weave. “By providing more flexible and affordable payment options, we are empowering patients to take control of their healthcare and ensuring that cost doesn’t prevent them from receiving the care they need.”
By expanding the payment options available to patients, Weave and Affirm aim to remove barriers to care and ensure everyone has access to the healthcare services they need. The partnership reflects the shared commitment of both companies to make patients’ payment experience more seamless and revolutionize the way healthcare practices handle payments.
“By partnering with Weave, thousands of healthcare practices can now seamlessly add Affirm’s transparent and flexible payment options at checkout,”
said Wayne Pommen, Chief Revenue Officer of Affirm.
Patients are eager to pay over time without junk fees, late fees, or compounding interest, and now these businesses can address that demand.
[Source – Business Wire]
Weave is the all-in-one experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.
Affirm’s mission is to deliver honest financial products that improve lives. By building a new kind of payment network — one based on trust, transparency and putting people first — we empower millions of consumers to spend and save responsibly, and give thousands of businesses the tools to fuel growth. Unlike most credit cards and other pay-over-time options, we show consumers exactly what they will pay up front, never increase that amount, and never charge any late or hidden fees.
Xenex | September 11, 2023
United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot.
The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles.
The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise.
Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health.
As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens.
Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores.
This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings.
Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device.
Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies.
Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.